Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial
- 7 November 2008
- Vol. 27 (2) , 243-249
- https://doi.org/10.1016/j.vaccine.2008.10.051
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIVKU2 infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktailVirology, 2007
- An HIV Vaccine — Evolving ConceptsNew England Journal of Medicine, 2007
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus VectorThe Journal of Infectious Diseases, 2006
- A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccineVaccine, 2006
- Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosisThorax, 2006
- A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaquesVaccine, 2004
- Moving to Human Immunodeficiency Virus Type 1 Vaccine Efficacy Trials: Defining T Cell Responses As Potential Correlates of ImmunityThe Journal of Infectious Diseases, 2003
- Neutralizing antibodies to granulocyte–macrophage colony‐stimulating factor, interleukin‐1α and interferon‐α but not other cytokines in human immunoglobulin preparationsImmunology, 2000
- Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIVJournal of Interferon & Cytokine Research, 1999
- Peptide Component Vaccine Engineering: Targeting the AIDS VirusInternational Reviews of Immunology, 1990